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creativecommons.org/licenses/by-nc-nd/4.0/).A B S T R A C TKeywords: Low serum high density lipoprotein cholesterol level (HDL-C) <40 mg/dL in men and <50
mg/dL in women is a significant independent risk factor for cardiovascular disease (CVD),
and is often observed in patients with hypertriglyceridemia, obesity, insulin resistance, and
diabetes. Patients with marked deficiency of HDL-C (<20 mg/dL) in the absence of secondary
causes are much less common (<1% of the population). These patients may have
homozygous, compound heterozygous, or heterozygous defects involving the apolipopro-
tein (APO)AI, ABCA1, or lecithin:cholesterol acyl transferase genes, associated with apo A-I
deficiency, apoA-I variants, Tangier disease , familial lecithin:cholesteryl ester acyltrans-
ferase deficiency, and fish eye disease. There is marked variability in laboratory and clinical
presentation, and DNA analysis is necessary for diagnosis. These patients can develop
premature CVD, neuropathy, kidney failure, neuropathy, hepatosplenomegaly and anemia.
Treatment should be directed at optimizing all non-HDL risk factors.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Lipoproteins
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Genetic dyslipidemiasHigh density lipoproteins (HDL) are generally spherical
lipoprotein particles with a diameter of about 6–11 nm, and
usually have α mobility on electrophoresis. HDL has been
defined as having a density of 1.063–1.21 g/mL in plasma.
Normal HDL particles contain (weight %) about 50% protein,
25% phospholipid, 20% cholesterol, and 5% triglyceride (TG).
About 70% of the cholesterol is in the esterified form. In HDL
the protein, phospholipid, and free cholesterol are on the
surface, with cholesteryl ester (CE) and TG in the core. The
major proteins of HDL are apolipoprotein (apo) A-I and
apoA-II, present in a molar ratio of about 3:1, with many
other proteins including apoA-IV, apoA-V, apoC-I, apoC-II,
apoC-III, and apoE being found on HDL particles in much
smaller amounts. The production and plasma residence timee 104.
fer, MD, Tufts University
(E.J. Schaefer).
by Elsevier Inc. This isof HDL apoA-I in normal subjects are about 12 mg/kg/day and
4.0 days, respectively, while for apoA-II these values are about
3.0 mg/kg/day and 4.5 days, respectively. Other apolipopro-
teins within HDL have much lower plasma residence with
these values of about 0.5–2.0 days. HDL has been further
divided into HDL2 of density 1.063–1.125 g/mL and HDL3 of
density 1.125–1.21 g/mL. In patients with low HDL, there is a
much greater decrease in HDL2 than in HDL3.
HDL is quantified in the general laboratory by measuring
its cholesterol content using automated enzymatic analyses
after removing all other lipoproteins by precipitation. An
HDL-C level of <40 mg/dL in men and <50 mg/dL in women
has been defined as decreased, and has been associated with
an increased risk of cardiovascular disease (CVD). HDL-C is, 711 Washington Street, Boston, MA 02111.
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Abbreviations and Acronyms
ABC = ATP binding cassette
APO = apolipoprotein
CE = Cholesterol ester
CETP = Cholesterol ester
transport protein
CHD = Coronary heart disease
CVD = Cardiovascular disease
DM = Diabetes mellitus
FED = Fish Eye Disease
FH = Familial
Hypercholesterolemia
FLD = Familial Lecithin:
Cholesteryl Ester Acyltransferase
Deficiency
HDL = High –density lipoprotein
HDL-C = High –density
lipoproteincholesterol
LCAT = lecithin:cholesterol acyl
transferase
LDL = Low-density lipoprotein
LDL-C = Low-density lipoprotein
cholesterol
LIPG = endothelial lipase gene
Lp(a) = Lipoprotein a
MI = Myocardial infarction
SR = Scavenger receptor
TD = Tangier Disease
TG = Triglyceride
VLDL = Very low-density
lipoprotein
VLDL-C = Very low-density
lipoprotein cholesterol
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used in the risk
calculator for CVD
risk.1 It has been rec-
ommended by the
guidelines that sub-
jects with CVD, diabe-
tes mellitus (DM),
an elevated low den-
sity lipoprotein cho-
lesterol (LDL-C ≥190
mg/dL) and an esti-
mated 10 year CVD
risk of ≥7.5% be consid-
ered for statin therapy
in addition to lifestyle
modification.1,2 Recent
expert opinion guide-
lines indicate that non
statin agents such as
ezetimibe, anion ex-
change resins, and
proprotein convertase
subtilisin kexin 9 in-
hibitors can be used
along with statins to
get at least a 50% de-
crease in LDL-C with
an option to get LDL-C
levels to <70 mg/dL in
CVD patients and to
<100 mg/dL in high
risk patients.3
A common obser-
vation in the statin
intervention trials
was that patients
with dyslipidemia (el-
evated TGs >200 mg/
dL and decreased
HDL-C <35 mg/dL)
had the highest resid-
ual CVD risk. More-
over the addition of
fenofibrate to statintherapy in DM subjects was not shown to provide significant
benefit in CVD risk reduction, except in the dyslipidemic
subgroup.4 The same was true for the addition of niacin to
statin therapy in CVD patients selected for having an HDL-C
level <40mg/dL.5 Only those subjectswith TG values >200mg/dL
and HDL-C values <32 mg/dL got benefit.5 Interestingly, in the
Japan Eicosapentaenoic Acid (EPA) Lipid Intervention Trial, the
addition of EPA to statin therapy in hypercholesterolemic
patients did lower CVD risk by 19%; however this risk reduction
wasmost striking (−53%) in patients with dyslipidemia, despite
no clinically significant effects on lipid levels.6
In studies of families with premature CVD it was originally
documented that about 15% of these families had familial
combined hyperlipidemia with elevations of both totalplasma cholesterol and TG levels, and about 1% had familial
hypercholesterolemia (FH).7 In our own studies of families
with premature CVD (age <60 years), we measured plasma
concentrations of total cholesterol, TG, LDL-C, HDL-C, apoB,
and lipoprotein (a) or Lp(a). We noted that 19% of families had
Lp(a) excess, 15% had familial dyslipidemia (high TGs and low
HDL-C), 14% had familial combined hyperlipidemia (mostly
also with low HDL), 5% had isolated apoB elevation, 4% had
isolated low HDL (hypoalphalipoproteinemia), and 1% had
FH.8,9 Cut points utilized were 10th and 90th percentile values
for normal age and gender matched controls from the
Framingham Offspring Study. These data indicate that low
HDL-C in families with premature CVD is frequently associated
with either elevated TGs or elevations of both TGs and LDL-C.
Our own early studies indicated that patients with very
high TG levels (>500 mg/dL) had very low HDL-C values.10
These patients were subsequently shown to have markedly
enhanced clearance of HDL apoA-I.11 Moreover in the
Framingham Offspring Study low HDL-C levels were signifi-
cantly associated with hypertriglyceridemia, obesity, DM,
male gender, sedentary lifestyle, and cigarette smoking.12 In
menselected for CVD, lowHDL-C (<40mg/dL), LDL-C<140mg/dL,
and TG levels <150 mg/dL in the Veterans Affairs HDL
Intervention Trial (VA-HIT), almost all subjects were over-
weight or obese, many were insulin-resistant, and 25% were
diabetic.13Moreover in this trial the occurrence of newCVD and
the benefit of fibrate therapy were much less dependent on
levels of HDL-C or TGs than on the presence or absence of
insulin resistance.13 The overall data indicate that HDL-C levels
in the general population are more strongly affected by TGs,
body mass index and insulin resistance than genetic factors.HDL Particle Analysis
HDL particles have been characterized by ultracentrifugation,
nuclear magnetic resonance, one dimensional gel electropho-
resis, high performance liquid chromatography, and ion
mobility. These methods in our view lack the resolution and
specificity provided by two dimensional gel electrophoresis of
whole plasma followed by immunoblotting with apoA-I
specific antibodies, developed by Asztalos and Roheim.14 In
this analysis there are five major HDL particles which are
separated by size and charge. There are two major discoidal
HDL particles: 1) very small preβ-1 migrating HDL of about 5.6
nm in diameter containing only apoA-I and phospholipid
(about 6% of total apoA-I), and 2) small α-4 HDL of about 7.4
nm in diameter containing apoA-I, phospholipid, and free
cholesterol (about 14% of total apoA-I). Then there are three
larger spherical HDL particles all of which have α mobility: 1)
medium α-3 HDL of about 8.1 nm in diameter containing both
apoA-I and apoA-II, as well as phospholipid, free and
esterified cholesterol, and TG (about 16% of total apoA-I), 2)
large α-2 HDL of about 9.2 nm in diameter containing the
same constituents as α-3 HDL (about 40% of the total apoA-I),
and 3) very large α-1 HDL of about 11.0 nm in diameter
containing the same constituents as α-3 and α-2 HDL except
without apoA-II (about 16% of total apoA-I). About 8% of
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migrating HDL particles, with small amounts in large preβ-2
migrating HDL, as well as in TG-rich lipoproteins (see Fig 1).
Therefore the most abundant apoA-I containing HDL
particle in the plasma of normal subjects is α-2 HDL. Patients
with CVD have significantly lower levels of apoA-I in very
large α-1 HDL and large α-2 HDL, and significantly more
apoA-I in very small preβ-1 HDL than do control subjects14
(see Fig 1). HDL particle analysis in our view provides
significantly more information about CVD risk than
does HDL-C. A marked increase of these large HDL particles
with the simvastatin/niacin combination was associated
with regression of coronary atherosclerosis.14 Other modali-
ties that significantly raise very large α-1 HDL include
substantial weight loss, diets low in sugar, and rosuvastatin
therapy.14
Functional studies indicate that very small discoidal
preβ-1 HDL picks up free cholesterol from cells via the ATP
binding cassette A1 (ABCA1) transporter and in the process is
converted to small discoidal α-4 HDL. These latter particles
are then converted to larger spherical α HDL by the action of
lecithin:cholesterol acyl transferase (LCAT) which converts
free cholesterol to CE. Lipoprotein lipase (LPL) is also
necessary for this conversion. Larger α HDL can then donate
their cholesteryl ester to TG-rich lipoproteins (TRL) in
exchange for TG via the action of CE transfer protein (CETP)
or donate their CE and free cholesterol to the liver via
scavenger receptor-B1 (SR-B1).14 During this process apoA-I
in our view can recycle back to form very small and small HDL
discoidal particles, or be catabolized from plasma by the
kidney via the action of cubilin. Both hepatic lipase and
endothelial lipase play a role as phospholipases in removing
phospholipid from large HDL and converting them to smaller
HDL.14 Studies indicate that serum cholesterol efflux capacity
serves as a better marker of CVD risk than does HDL-C
levels.15,161-Dimension (Charge)
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Fig 1 – Two dimensional gel electrophoresis patterns of HDL par
premature coronary heart disease (CHD) (second from left) along
potential structure (far right) of apoA-I containing HDL particles
(diameter) is plotted on the vertical axis and the electrophoretic
The CHD patient clearly has a marked reduction in the apoA-I coDisorders Characterized by Marked HDL Deficiency
Patients with marked deficiency of high density lipoproteins
(HDL cholesterol <20 mg/dL) in the absence of marked
hypertriglyceridemia (>500 mg/dL), uncontrolled DM, liver
disease, or the use of anabolic steroids, are uncommon (<1%
of the population). These patients may have homozygous,
compound heterozygous, or heterozygous defects involving the
APOAI, ABCA1, or LCAT genes. Such patients can be divided into
five groups: 1) apoA-I deficiency, 2) apoA-I variants, 3) Tangier
disease (TD), 4) familial lecithin:cholesteryl ester acyltrasferase
deficiency (FLD), and 5) fish eye disease (FED). There are a
number of forms of familial apolipoproteinA-I deficiency: those
characterized by a lack of plasma apoA-I, apoC-III, and apoA-IV,
those characterized by a lack of apoA-I and apoC-III, and those
characterized by a lack of apoA-I only.17,18 These states are
briefly reviewed below.
Apolipoprotein A-I Deficiency States
We described a kindred in 1982 in which the female proband
hadmarkedHDLdeficiency, undetectable plasma apoA-I levels,
low-TG levels, normal LDL-C levels, corneal arcus, and prema-
ture CVD.17,18 The patient had severe CVD and planar
xanthomas and died during coronary artery bypass surgery at
age 43 years. She had no other known CVD risk factors, and on
autopsy was found to have very severe diffuse coronary and
peripheral atherosclerosis. Her plasma LCAT activity was
normal, and her defect was found to be due to a homozygous
deletion of the entire APOA1/C3/A4 gene complex. Heterozy-
gotes had plasma HDL-C, apoA-I, apoA-IV, and apoC-III levels
that were about 50% of normal. This disorder is known as
familial apolipoprotein A-I/C-III/A-IV deficiency.17,18
Norum and colleagues in 1982 described two sisters with
marked HDL deficiency, undetectable plasma apoA-I andSchematic
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ticles from a normal subject (far left) and a patient with
with two depictions of the position (middle right) and the
are shown. On the gel patterns the particle size in nm
mobility (preβ, α, and preα) is plotted on the horizontal axis.
ncentration in very large α-1 HDL.
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bypass surgery at ages 29 and 30 years. These patients had
low TG levels, normal LDL-C levels, and the defect was found
to be due to a homozygous DNA rearrangement affecting the
adjacent APOA1 and APOC3 genes. They had enhanced
clearance of very LDL (VLDL) apoB. This disorder is known as
familial apolipoprotein A-I/C-III deficiency.17,18
Matsunaga and colleagues in 1991 described a 56-year-old
Japanese woman with premature CVD, planar xanthomas,
normal TG and LDL-C levels, marked HDL deficiency, and
undetectable plasma apoA-I levels. The defect was a homo-
zygousAPOAI codon 84 nonsensemutation, resulting in a lack
of normal apoA-I production.17,18 Ng and colleagues in 1994
reported a Portuguese kindred in which a 34-year-old proband
had undetectable plasma apoA-I levels, marked HDL deficien-
cy, tendinous xanthomas, premature CVD, cerebellar ataxia,
and elevated LDL-C levels. The defect was a codon −2 APOA1
nonsense mutation resulting in lack of apoA-I production.
Two other homozygotes in this kindred also had CVD in their
30s.17,18 The elevated LDL-C values were felt to be due to
another genetic disorder.17,18 We reported another Portuguese
kindred with the same mutation as in the prior kindred (−2
codon nonsense mutation) in two homozygous brothers who
presented with undetectable plasma apoA-I (see Fig 2), CVD
requiring bypass surgery at 38 and 39 years of age,
tubo-eruptive and planar xanthomas, corneal arcus and
mild corneal opacification (see Fig 3), with HDL-C <5 mg/dL
and normal LDL-C and TG levels. They had no detectable
apoA-I containing HDL (see Fig 3). Multiple heterozygotes in
this kindred had HDL-C levels that were about 50% of
normal.17,18
An Iraqi kindred with two probands was reported in 2010
who were noted to have complete apoA-I deficiency and
marked HDL deficiency caused by a homozygous nonsense
mutation with a stop codon at Arg10. One proband was a 35
year old woman with xanthelasma and xanthomas, but no
CVD, while her 37 year old brother also had planar
xanthomas, but sustained a myocardial infarction (MI) at age
35 years. Both patients had normal LDL-C and triglyceride
levels. In contrast to the sister, the brother was a cigarette
smoker and had an Lp(a) of 53 mg/dL.19
These data indicate that undetectable plasma apoA-I
levels and marked HDL deficiency due to homozygous
mutations affecting APOA1 are associated with premature
CVD. Such patients in our view should have their LDL-C levels
optimized with statin therapy, and if necessary with other
agents. In the future apoA-I or HDL infusion therapy may be
available for such patients since such therapy had been
shown to have benefit for CVD in small studies.20
Apolipoprotein A-I Variants
Funke and colleagues in 1991 reported a 42-year-old German
patient with corneal opacification, marked HDL deficiency
and apoA-I deficiency, significantly decreased plasma LCAT
activity, increased non-HDL-C and TGs, and lack of CVD.20
Sequencing of his LCAT gene was normal, but the patient was
found to be homozygous for an apoA-I frameshift mutation
resulting in a truncated 229 amino acid protein instead of fulllength apoA-I.21 Heterozygotes in the kindred had about 50%
of normal HDL-C levels. Takata and colleagues in 1995
reported a 39-year-old Japanese man with corneal
opacification, a serum HDL-C of 6 mg/dL, an apoA-I level of
<3.0 mg/dL, increased LDL-C, with normal levels of plasma
TG, phospholipid, apoB, apoC-III, and apoE levels. LCAT
activity was about 50% of normal. The patient was homozy-
gous for a codon 8 nonsense mutation in exon 3 of the apoA-I
gene. Heterozygotes in the family had normal HDL-C values.
Coronary angiography showed no significant luminal
narrowing.22
In 2013 we reported a 61-year-old male with significant
coronary heart disease since age 42 years, corneal arcus,
combined hyperlipidemia, an HDL-C of 1 mg/dL, an apoA-I of
23mg/dL, and only preβ-1 and α-2 HDL particles present in his
HDL particles.23 He was found to have a novel heterozygous
inframe insertion mutation with a duplication of nucleotides
1535 through 1552 inserted at position 1553, causing a new
amino acid glycine at residue 157 and a duplication of amino
acids alanine, arginine, alanine, histidine, and leucine at
residues 158–162. His LCAT activity was normal. This novel
apoA-I mutation (apoA-INashua) appears to result in the
formation of apoA-I that has abnormal lipid binding proper-
ties, resulting in probable impaired reverse cholesterol
transport, and premature CVD.23 His TG and LDL-C levels
have been optimized with rosuvastatin and fenofibrate
therapy.
In 2014 we reported a 68-year-oldmale with premature CVD
since age 54 years, corneal arcus, and an HDL-C 14 mg/dL,
apoA-I 57 mg/dL, and lack of very large α-1 HDL.24 His TG and
LDL-C levels were normal, but have been further optimized
with statin therapy. Two other family members also had the
same pattern. The affected kindred members were noted to
have an apoA-I truncation (apoA-IMytilene) due to a heterozy-
gous nonsense mutation (Gln216termination) resulting in a
truncated apoA-I containing only 215 amino acids. Kinetic
studies indicated that the proband had an apoA-I production
rate that was 40% of normal. The patient had cellular
cholesterol efflux capacity that was 65% of normal, and
normal LCAT activity.24
ApoA-I variants are generally heterozygous premature
terminations, frameshifts or amino acid substitutions in the
243 amino acid apoA-I sequence. These patients may have
HDL-C levels that are low or normal, plasma LCAT activity that
is normal or reduced, and they may develop premature CVD or
amyloidosis. Heterozygous premature apoA-I terminations or
frameshiftmutationswith lowHDL-C include Trp8termination,
Gln32termination, Gln84termination, Glu136termination, and
Gln216termination.17,18 Heterozygous apoA-I variants associat-
ed with low HDL-C include Arg10Leu, Arg27Thr, Leu144Arg,
Arg149Ser, Arg151Cys, Val156Glu, Leu159Arg, Arg160Leu,
Pro165Arg, and Arg173Cys (apoA-I Milano). ApoA-I is known to
be one of the apolipoproteins that can activate LCAT. Hetero-
zygous APOA1 mutations associated with decreased LCAT
activation are located within α helices 5–7, corresponding to
amino acids 121 to 187 of apoA-I. Six heterozygous apoA-I
missense mutations, namely Leu141ArgPisa, Pro143Arg,
Arg151Cys, Val156Arg, Arg160LeuOslo, and Pro165Arg, have
been associated with low HDL-C and decreased LCAT activity.
Fig 2 – Two dimensional gel electrophoretic patterns of apoA-I containing HDL particles (from left to right) are shown from a
control subject, an apoA-I deficient patient (no particles), a TD patient (only preβ-1 HDL), an FLD patient (preβ-1 and α-4 HDL,
with some larger discoidal fusion particles), an LPL deficient patient with lack of large α HDL, an HL deficient patient with
decrease in α-2 HDL, and a patient with CETP deficiency with an excess of abnormal very large HDL particles.
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patient with homozygous Val156Glu had corneal opacification
consistent with FLD. It is also quite likely that apoA-IMilano
(Arg173Cys) falls into this category, and heterozygoteswith this
disorder appear to be protected from CVD.17,18 Interestingly
patients who are compound heterozygotes for Leu141ArgPisa
and an apoA-I null allele were reported to have very low HDL-C
and apoA-I levels that were 3% of control value. All of theseFig 3 – Images of corneal arcus and corneal opacification are sho
apolipoprotein A-I deficiency with somewhat atypical arcus juve
TD showing diffuse corneal opacification only seen by slit lamp
homozygous FLD with marked corneal arcus juvenilis and corne
with compound heterozygous FED with marked arcus juvenilis alatter subjects had marked corneal opacification and three of
the four compound heterozygotes had significant premature
CVD.17,18 These data indicate that heterozygous apoA-I variants
causing low HDL-C and decreased LCAT activation are not
associated with premature CVD. However apoA-I variants
associated with low HDL-C and normal LCAT activity have
been associated with premature CVD and include Leu141Arg,
Arg153Pro, Leu159Pro, and Leu178Pro, as well as thosewn. In the upper left is a patient with homozygous
nilis. In the upper right panel is a patient with homozygous
examination. In the lower left panel is a patient with
al opacification. In the lower right panel is a young patient
nd some diffuse corneal opacification.
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normal HDL and increased CVD risk is Ala164Ser to be
discussed later as well.25
ApoA-I mutations can also cause familial visceral amyloid-
osis, a form of amyloidosis that is an uncommon cause of
kidney failure.26 Certain apoA-Imutations lead to the formation
of apoA-I–amyloid protein complexes, causing enhanced amy-
loid proteolysis, and amyloid deposition of 9–11 kd N terminal
fragments as fibrils in the kidney, liver, and heart, damaging
these organs. In such patients the amyloid deposits exhibit a
characteristic green birefringence when viewed by microscopy
under polarized light after Congo red staining. These deposits
are immunoreactive with antibodies against apoA-I. Das and
colleagues have reported that all amyloidogenic apoA-I muta-
tions cluster in residue segments 26–107 and 154–178, and can
destabilize lipid free and HDL bound apoA-I.27 The apoA-I
variants reported to be associated with amyloidosis include
Gly26Arg, Trp50Arg, Leu60Arg. Leu64Pro, Asn74 frameshift,
Leu75Pro, Leu90Pro, Ala154 frameshift, Leu170Pro, Arg173Pro,
Leu174Ser, Ala175Pro, and Leu178His.17,18,26,27Tangier Disease (TD)
TDwas first described by Fredrickson and colleagues in 1961 in
two young siblings from Tangier Island in the Chesapeake Bay,
noted to have very low plasma of HDL-C, moderate hypertri-
glyceridemia, and decreased LDL-C levels.17,18 They had mild
corneal opacification (see Fig 3), hepatosplenomegaly and
enlarged orange tonsils. Cholesterol-laden macrophages were
found in cells in their tonsils, bonemarrow, nerves, and smooth
muscle cells. The heterozygous parents had approximately half
normal levels of HDL-C. Other kindreds were described, and in
somecasesneuropathywasnoted.Wenoted thathomozygotes
had markedly increased fractional catabolism of HDL proteins
(plasma apoA-I residence times of about 0.5 days), while
heterozygotes had enhanced clearance (plasma residence
times of about 2.0 days). We also found that Tangier homozy-
gotes had an increased risk of developing premature CVD in
their 50s and 60s. They speculated that these patients may not
develop CVD earlier in life because their LDL-C levels were
about 50% of normal.17,18
In the 1990s Francis and Oram, as well as Schmitz and
Assmann, independently noted that TD fibroblasts were
defective in their ability to efflux cellular cholesterol and
phospholipids onto HDL or apoA-I.17 In 1998 the chromosom-
al locus (9q31) for TD was reported by Rust, Assmann, and
colleagues. Subsequently it was reported by Schmitz and
colleagues that the ABCA1 was involved in the efflux of
cellular cholesterol and phospholipid onto HDL and apoA-I. In
1999 and 2000 six different research groups reported that
various mutations in ABCA1 were the causes of homozygous
TD, with the first three reports by Rust, Assmann and
colleagues, Bodzioch, Schmitz and colleagues, and Brooks,
Hayden and colleagues appearing simultaneously in 1999 in
Nature Genetics.17,18
We were one of the groups subsequently reporting these
mutations, and we also documented that TD homozygoteshad only preβ-1 HDL present in their plasma (see Fig 2), while
heterozygotes had a lack of large α-1 and α-2 HDL particles,
normal preβ-1 HDL, and only 50% of normal cellular choles-
terol efflux.17,18 We also noted that intestinal cholesterol
absorption was normal in a Tangier homozygote, and that the
LDL apoB values were about 50% reduced due to enhanced
fractional catabolism of small TG-rich, cholesteryl ester-poor
LDL.We have speculated that the lack of uptake of cholesterol
from cells by HDL in these patients, not only results in the
rapid clearance of very small preβ-1 HDL particles by the
kidney, but also relative enrichment of the core of LDL by
beta-carotene, resulting in enhanced uptake by the
reticulo-endothelial cells resulting in the orange coloration
of these tissues.17,18
There is significant controversy in the literature about
whether patients with homozygous Tangier disease develop
premature CVD. We have again recently reviewed this
relationship in our own cases and those in the literature
(total of 185 cases). In this review 51% of reported cases had
peripheral neuropathy and 25% had CVD, which increased to
52% in those between the ages of 40 and 65 years, as
compared to 11% in age and gender matched controls. Two
main types of patients with homozygous or compound
heterozygous Tangier disease and marked HDL deficiency
were noted in our recent unpublished review: 1) group A
patients with marked hepatosplenomegaly, anemia, low
non-HDL-C levels (<70 mg/dL) and lack of premature coronary
heart disease (CHD); and 2) group B patients without marked
hepatosplenomegaly or anemia, normal or near normal
non-HDL-C levels (>70 mg/dL), and premature CHD. These
data indicate that the presence or absence of marked
splenomegaly and the varying non-HDL-C levels appear to
account for the variability in CVD risk in homozygous Tangier
disease patients. Optimizing the LDL-C levels in Tangier
patients with normal LDL-C levels using statin therapy is
clearly warranted in our view.Familial Lecithin:Cholesterol Acyltransferase
Deficiency (FLD)
FLD was first described by Norum and Gjone in 1967 in a
33-year-old woman living in Norway, who presented with
marked corneal opacification, hyperlipidemia, anemia, pro-
teinuria, and normal kidney function. A kidney biopsy
revealed foam cells in the glomeruli.17,18 Plasma cholesterol
and TG levels were moderately increased, with most of the
cholesterol being unesterified. Two of her sisters were
similarly affected, and all three were found to have a marked
deficiency of LCAT activity, lacking the ability to transfer a
fatty acid from phosphatidylcholine or lecithin to cholesterol
to form CE and lysolecithin. Kindreds in other countries were
subsequently described, and subsequently were found to
have homozygous or compound heterozygous mutations in
LCAT.
These patients were found to have not only very low levels
of HDL-C, but also were noted to have elevations in free
cholesterol-enriched VLDL, which had β instead of pre β
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be large and heterogeneous and enriched in free cholesterol,
phospholipids, and TG, with a very low CEcontent. These
particles have also been found to be low in apoBand enriched in
the C apolipoproteins. The corneal opacification observed in
FLD presents early in life and consists of numerous, minute,
grayish dots in the entire corneal stroma and is much more
striking than that observed inTDor the apoA-I deficiency states
(see Fig 3). The opacification is especially marked near the
limbal area, forming a circular band resembling arcus senilis.
Surprisingly vision is usually not impaired.
The anemia in these patients is moderate with hemoglo-
bin levels of around 10 g/dL and is associated with enhanced
fractional clearance of red cells. The renal disease presents as
proteinuria early in life, and increases in the fourth or fifth
decades of life as renal function deteriorates. Atherosclerosis
has been reported in some patients with familial LCAT
deficiency with aortic, carotid, and femoral atherosclerosis
but CHD prior to age 60 years has not been reported. Multiple
mutations have been reported. Hypercatabolism of HDL
proteins, especially apoA-II, has been reported in homozy-
gotes. We have documented that homozygotes have apoA-I in
plasma present only in preβ-1 and α-4 discoidal HDL particles
(see Fig 2).17,18 Two-dimensional gel electrophoresis of whole
plasma followed by immunoblotting with specific antibody
for apoA-I can therefore readily be used to distinguish
homozygous apoA-I deficiency, ABCA1 deficiency, or LCAT
deficiency (see Fig 2). We have reported with Calabresi that
heterozygotes for LCAT deficiency have less than 50% of
normal large a-1 HDL, but two-fold increases in very small
preb-1 HDL.17,18
Alpha-Core, a company in Ann Arbor, MI developed LCAT
enzymatic replacement therapy, and carried out individual
treatment studies in CVD patients and prolonged therapy in a
52 year old FLD homozygous patient with moderately
impaired renal function that we referred to the National
Institutes of Health.28 The weekly or bi-monthly enzyme
therapy was well tolerated in the FLD patient, but enzyme
supply ran out, and the patient ended up on dialysis. The
treatment did result in improvement of his anemia, stabili-
zation of his kidney function, and transient normalization of
his HDL particles after treatment.29 The rights to this therapy
have been purchased by MediImmune, a subsidiary of
AstraZeneca, and hopefully they will develop and commer-
cialize this treatment which may prevent renal failure in
homozygous FLD patients.Fish Eye Disease (FED)
Fish eye disease (FED) was first described by Carlson and
Philipson in 1979 in a male Norwegian patient and his three
daughters who had all marked corneal opacification.17,18 He
and his two living daughters were noted to have normal
serum cholesterol, elevated TG, elevated VLDL cholesterol
(VLDL-C), and LDL levels, and marked HDL deficiency. This
disease was characterized by these authors as being associ-
ated with CVD in later life, visual impairment, and densecorneal opacification. The eye findings can be variable.
Compared to HDL from control subjects the HDL particles of
FED were characterized by their abnormally small size and
enrichment of free cholesterol. Findings in these kindreds
have led to the formulation of the concept that two different
LCAT activities exist in normal plasma. One of these
activities, denoted α-LCAT, is specific for HDL, and the other,
β-LCAT, is specific for chylomicrons, VLDL, and LDL. FED has
been classified as an α-LCAT deficiency, in contrast to the
classical LCAT deficiency or FLD, where patients lack both α
and β LCAT activities. We described a kindred from Oklahoma
with two compound heterozygotes due to mutation in the
LCAT gene.30 They had somewhat elevated TGs and LDL-C,
and only preβ-1 and α-4 HDL, and responded well to statin
therapy to optimize their LDL-C levels and reduce their CVD
risk.30Genetic Variation in Genes Affecting HDL-C and
CVD Risk
In VA-HIT we documented that the prevalence of certain
genetic variants in the genes coding for lipoprotein lipase (LPL,
D9N, N291S, and S447X), ATP binding cassette transporter A-I
(ABCA1, G596A, A2589G and G3456C), and CETP (TaqI B2B2
genotype) were significantly different in CVD patients with
low HDL-C as compared to control subjects.29–33 In VA-HIT in
order to identify allelic variants associated with susceptibility
to low HDL-C and CVD, we further examined 60 candidate
genes with key roles in HDL metabolism, insulin resistance,
and inflammation using VA-HIT samples (cases, n = 699) and
from normal participants in the Framingham Offspring Study
(controls, n = 705). After adjustment for multiple testing
within each gene, single-nucleotide polymorphisms (SNP)
significantly associatedwith case status were identified in the
genes encoding LIPC (hepatic lipase, rs4775065, P < 0.0001);
CETP (rs5882, P = 0.0002); ABCA1 (rs2249891, P = 0.0126); CUBN
(rs7893395, P = 0.0246); and APOA2 (rs3813627, P = 0.0324),
among others.34
Cohen and colleagues sequenced the APOA1, ABCA1, and
LCAT genes in DNA obtained from subjects with HDL-C <5th
percentile and from subjects with HDL-C levels >95th percen-
tile. Non-synonomous variants were significantly more com-
mon (12% versus 2%) in individuals with low HDL-C (n = 284)
than in those with high HDL-C (n = 236). In subjects with low
HDL-C 9.9% had ABCA1 mutations, 2.2% had LCAT mutations,
and 0.2% had APOA1 mutations.35 Haase and colleagues
sequenced the APOA1 gene in 10,330 population-based
participants in the Copenhagen City Heart Study.25 Only
0.27% of individuals in the general population were heterozy-
gous for non-synonomous variants which were associated
with substantial reductions in apoA-I (up to 39 mg/dL) and/or
HDL-C(up to 35 mg/dL). Only 0.41% of the population was
heterozygous for variants predisposing to amyloidosis.
Non-synonomous variants were associated with a hazard
ratio of 1.72 (CI, 1.09–2.70, p < 0.01) for MI, largely driven by
Ala164Ser, a variant usually not associated with low apoA-I or
HDL-C levels.25
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in a Danish general population followed for 25 years. Two
ABCA1 variants (V771M and V825I) were previously associated
with increases in HDL-C, and one (R1587K) with decreased
HDL-C, whereas three variants (R219K, I883M and E1172D) did
not affect HDL-C levels. Despite this, 5 out of 6 SNPs (V771M,
V825I, I883M, E1172D, R1587K) predicted increased risk of IHD.
Similar results were obtained in a verification sample with
932 CVD cases versus 7999 controls. A stepwise regression
approach identified V771M, I883M, and E1172D as the most
important predictors of CHD and additive effects on CHD risk
were present for V771M/I883M and I883M/E1172D pairs.36
In another large population analysis these same investi-
gators looked at CVD risk in heterozygotes versus noncarriers
for four ABCA1 variants (P1065S, G1216 V, N1800H, R2144X).
These variants reduced HDL-C levels by 17-mg/dL, and this
reduction was associated with a multifactorially adjusted
hazard ratio for CVD of 1.70 (p < 0.001). However after
multiple adjustments, the lower plasma levels of HDL-C due
to heterozygosity for loss-of-function mutations in ABCA1
were not associated with an increased risk of CVD.37 These
same investigators reported that the ABCA1 variant N1800H
tested in 92,726 individuals for Alzheimer's disease risk and in
64,181 individuals to examine risk of cerebrovascular disease.
They documented that N1800HAC (0.2%) versus AA (99.8%) was
associated with a 13% lower plasma level of apoE (p < 0.00001),
and a multifactorially adjusted hazard ratios of 4.13 for
cerebrovascular disease, and 8.28 for the hemorrhagic stroke
subtype (both p < 0.00001).Moreover they documented that this
ABCA1 loss of function variant, present in 1:500 individuals,was
associated with low plasma levels of apoE and with high risk of
Alzheimer's disease in the general population.38
We assessed the ABCA1 Arg219Lys variant in 5414 partic-
ipants in PROSPER (PROspective Study of Pravastatin in the
Elderly at Risk) (mean age 75.3 years), who had been
randomized to pravastatin 40 mg/day or placebo and were
followed for a mean of 3.2 years. Of these subjects 47.6%
carried the variant, with 40.0% carrying one allele, and 7.6%
carrying both alleles. A modest but significant effect was seen
on HDL-C levels (p = 0.024). On trial those with the variant had
an overall adjusted hazard ratio for new CVD that was 1.22
versus those without the variant (p = 0.006), and in the
pravastatin group it was 1.41 (p = 0.001) versus those without
the variant. These data indicate that subjects with the variant
may get significantly less CVD risk reduction from pravastatin
treatment than those without the variant.39
Based on a mendelian randomization analysis it was
concluded that HDL is not a causative factor for atheroscle-
rosis and CVD.40 However in our view these studies were
highly flawed because they excluded the most important
genes affecting HDL metabolism, namely APOAI, ABCA1,
LCAT, LPL, CETP, and hepatic lipase gene (LIPC), focusing
instead mainly on the effects of a single genetic variant
(Asn396Ser) in the LIPG gene, whose role in human HDL
metabolism is uncertain. Their analysis indicated that this
variant while affecting HDL-C levels, had no significant effect
on CVD risk. They did note a significant relationship of
genetic variation at many of the other gene loci with CVD,
however they were excluded from the analysis because oftheir role in modulating the levels of other lipoproteins such
as VLDL. In our view one has to consider the effects of genetic
variation at each gene locus because the metabolism of
individual lipoproteins is highly linked.40Conclusions
Low HDL-C levels <40mg/dL are clearly an important CVD risk
factor, and are often associated with hypertriglyceridemia,
obesity, insulin resistance and DM. Marked HDL deficiency
with HDL-C levels <20 mg/dL is rare and can be associated
with a wide variety of clinical disorders. Patients who lack
apoA-I due to APOA1mutations have marked HDL deficiency,
normal LDL-C, normal LCAT activity, and premature CVD.
Patients with marked apoA-I deficiency due to apoA-I
variants with normal LDL-C, and normal LCAT activity, also
usually have premature CVD. However such patients with
decreased plasma LCAT activity, usually do not have prema-
ture CVD. TD patients with defects in ABCA1 have only preβ-1
HDL in their plasma. TD patients with marked splenomegaly
usually have significant anemia and thrombocytopenia, and
very low LDL-C levels (<30 mg/dL). These patients usually do
not develop premature CVD. In contrast TD patients without
significant splenomegaly usually do not have anemia, but
have normal LDL-C levels and usually develop premature
CVD. Patientswithhomozygous FLDdue to LCATdefects donot
form normal HDL or LDL, and have only preβ-1 and α-4 HDL in
their plasma. They do not develop premature CVD, but do
develop kidney failure in the 4th and 5th decades of life. In
contrast patients with homozygous FED do not form normal
HDL, but do formnormal LDL, and can develop premature CVD.
All patients in the above categories at increased CVD risk with
normal LDL-C levels in our view should have these levels
reduced to <50mg/dLwith statin therapy to decrease their risk.Statement of Conflict of Interest
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